Company intelligence / Profile preview
NuCana
Edinburgh, Scotland, United Kingdomnucana.com ↗
- Ownership
- Public · NCNA
- Employees
- ~75
- Development stage
- Phase 2
01
Overview
NuCana’s lead programs are showing encouraging anti-cancer activity in patients with advanced solid tumors and those resistant to prior immunotherapies. NUC‑3373 has demonstrated promising efficacy signals in second-line colorectal cancer and improved inhibition of thymidylate synthase compared to standard 5-FU. NUC‑7738 has shown activity as monotherapy and in combination with pembrolizumab for melanoma patients who failed previous PD‑1 inhibitor therapy. Both agents are advancing through Phase 1b/2 studies.
- Therapeutic areas
- Oncology
- Modalities
- small molecules (specifically ProTides—proprietary phosphoramidate nucleoside analogs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Not explicitly listed; collaboration with Merck for pembrolizumab use in trials implied but not formal partnership disclosed.
04
Financials
- Market cap
- $5.7M
- Total revenue
- $0
- Enterprise value
- $-19.4M
Beyond the preview
Go deeper on NuCana.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NuCana.